Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists

Steroids

Volumn 96, Issue , 2015, Pages 121-131

  Renga, Barbara ^a   Festa, Carmen ^b   De Marino, Simona ^b   Di Micco, Simone ^c   D'Auria, Maria Valeria ^b   Bifulco, Giuseppe ^c   Fiorucci, Stefano ^a   Zampella, Angela ^b  

^a Department of Surgery and Biomedical Sciences   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Gymnema sylvestre; Gymnemic acids; Liver X receptor; Steroid nuclear receptors

Indexed keywords

ABC TRANSPORTER A1; AGLYCONE GYMNEMAGENIN; GYMNEMA SYLVESTRE EXTRACT; GYMNEMAGENIN 3 O GLUCURONIDE; GYMNEMIC ACID; GYMNEMIC ACID I; GYMNEMIC ACID II; GYMNEMIC ACID III; GYMNEMIC ACID IV; GYMNEMIC ACID V; GYMNEMIC ACID VII; GYMNEMIC ACID VIII; GYMNEMIC ACID XI; GYMNESTROGENIN; LIVER X RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; PROTEIN INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; ORPHAN NUCLEAR RECEPTOR; SAPONIN; TRITERPENE;

ARTICLE; CONCENTRATION RESPONSE; DRUG HYDROLYSIS; DRUG POTENCY; DYSLIPIDEMIA; GYMNEMA SYLVESTRE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; PROTEIN EXPRESSION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; PROTEIN CONFORMATION; TRANSCRIPTION INITIATION;

DRUG DISCOVERY; GYMNEMA SYLVESTRE; HEP G2 CELLS; HUMANS; MODELS, MOLECULAR; ORPHAN NUCLEAR RECEPTORS; PROTEIN CONFORMATION; SAPONINS; TRANSCRIPTIONAL ACTIVATION; TRITERPENES;

EID: 84944317330     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2015.01.024     Document Type: Article

References (67)

1. [1] Kapoor, L.D., Handbook of ayurvedic medicinal plants. 1990, CRC Press, Boca Raton, FL p. 200.
2. [2] Kanetkar, P., Singhal, R., Kamat, M., Gymnema sylvestre: a memoir. J Clin Biochem Nutr 1 (2005), 77–81.
3. [3] Saneja, A., Sharma, C., Aneja, K.R., Pahwa, R., Gymnema sylvestre (Gurmar): a review. Der Pharmacia Lettre 2 (2010), 275–284.
4. [4] Porchezhian, E., Dobriyal, R.M., An overview on the advances of Gymnema sylvestre: chemistry, pharmacology and patents. Pharmazie 58 (2003), 5–12.
5. [5] Shigematsu, N., Asano, R., Shimosaka, M., Okazaki, M., Effect of administration with the extract of Gymnema sylvestre R. Br. leaves on lipid metabolism in rats. Biol Pharm Bull 24 (2001), 713–717.
6. [6] Persaud, S.J., Majed, H.A., Raman, A., Jones, P.M., Gymnema sylvestre stimulates insulin release in vitro by increased membrane permeability. J Endocrinol 163 (1999), 207–212.
7. [7] Shanmugasundaram, E.R.B., Gopinath, K.L., Shanmugasundaram, K.R., Rajendran, V.M., Possible regeneration of the islets of Langerhans in streptozocin-diabetic rats given Gymnema sylvestre leaf extracts. J Ethnopharmacol 30 (1990), 265–279.
8. [8] Baskaran, K., Ahamath, B.K., Shanmugasundaram, K.R., Shanmugasundaram, E.R.B., Antidiabetic effect of a leaf extract from Gymnema sylvestre in noninsulin dependent diabetes mellitus patients. J Ethnopharmacol 30 (1990), 295–305.
9. [9] Tiwari, P., Mishra, B.N., Sangwan, N.S., Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int, 2014, 10.1155/2014/830285.
10. [10] Di Fabio, G., Romanucci, V., De Marco, A., Zarrelli, A., Triterpenoids from Gymnema sylvestre and their pharmacological activities. Molecules 19 (2014), 10956–10981.
11. [11] Patil, A.N., Nirmal, S.A., Chavan, A.K., Development and validation of HPTLC method for estimation of gymnemic acid in microencapsulated antidiabetic polyherbal formulations. Acta Chromatogr 25 (2013), 601–612.
12. [12] Wang, Y., Dawid, C., Kottra, G., Daniel, H., Hofmann, T., Gymnemic acids inhibit sodium-dependent glucose transporter. J Agric Food Chem 62 (2014), 5925–5931.
13. [13] Preuss, H.G., Bagchi, D., Bagchi, M., Rao, C.V., Dey, D.K., et al. Effects of a natural extract of (–)-hydroxycitric acid (HCA-SX) and a combination of HCA-SX plus niacin-bound chromium and Gymnema sylvestre extract on weight loss. Diabetes Obes Metab 6 (2004), 171–180.
14. [14] Bishayee, A., Chatterjee, M., Hypolipidemic and antiatherosclerotic effects of Gymnema sylvestre leaf extract in albino rats fed on high fat diet. Phys Res 8 (1994), 118–120.
15. [15] Kalaany, N.Y., Mangelsdorf, D.J., LXRs and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68 (2006), 159–191.
16. [16] Tontonoz, P., Mangelsdorf, D.J., Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17 (2003), 985–993.
17. [17] Swanson, H.I., Wada, T., Xie, W., Renga, B., Zampella, A., et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos 41 (2013), 1–11.
18. [18] Janowski, B.A., Willy, P.J., Devi, T.R., Falck, J.R., Mangelsdorf, D.J., An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383 (1996), 728–731.
19. [19] Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272 (1997), 3137–3140.
20. [20] Venkateswaran, A., Laffitte, B.A., Joseph, S.B., Mak, P.A., Wilpitz, D.C., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 97 (2000), 12097–12102.
21. [21] Chawla, A., Boisvert, W.A., Lee, C.H., Laffitte, B.A., Barak, Y., et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (2001), 161–171.
22. [22] Costet, P., Luo, Y., Wang, N., Tall, A.R., Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275 (2000), 28240–28245.
23. [23] Laffitte, B.A., Repa, J.J., Joseph, S.B., Wilpitz, D.C., Kast, H.R., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98 (2001), 507–512.
24. [24] Repa, J.J., Turley, S.D., Lobaccaro, J.A., Medina, J., Li, L., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 (2000), 1524–1529.
25. [25] Joseph, S.B., Bradley, M.N., Castrillo, A., Bruhn, K.W., Mak, P.A., Pei, L., et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119 (2004), 299–309.
26. [26] A-Gonzalez, N., Bensinger, S.J., Hong, C., Beceiro, S., Bradley, M.N., Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31 (2009), 245–258.
27. [27] Laffitte, B.A., Chao, L.C., Li, J., Walczak, R., Hummasti, S., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100 (2003), 5419–5424.
28. [28] Commerford, S.R., Vargas, L., Dorfman, S.E., Mitro, N., Rocheford, E.C., et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 21 (2007), 3002–3012.
29. [29] Loren, J., Huang, Z., Laffitte, B.A., Molteni, V., Liver X receptor modulators: a review of recently patented compounds (2009–2012). Expert Opin Ther Pat 23 (2013), 1317–1335.
30. [30] Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., et al. Role of LXRs in control of lipogenesis. Genes Dev 14 (2000), 2831–2838.
31. [31] Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14 (2000), 2819–2830.
32. [32] Joseph, S.B., Laffitte, B.A., Patel, P.H., Watson, M.A., Matsukuma, K.E., et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277 (2002), 11019–11025.
33. [33] Grefhorst, A., Elzinga, B.M., Voshol, P.J., Plösch, T., Kok, T., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277 (2002), 34182–34190.
34. [34] Sim, W.C., Park, S., Lee, K.Y., Je, Y.T., Yin, H.Q., et al. LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver. Biochem Pharmacol 90 (2014), 414–424.
35. [35] Griffett, K., Solt, L.A., El-Gendy, Bel-D., Kamenecka, T.M., et al. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol 8 (2013), 559–567.
36. [36] D'Auria, M.V., Sepe, V., Zampella, A., Natural ligands for nuclear receptors: biology and potential therapeutic applications. Curr Top Med Chem 12 (2012), 637–669.
37. [37] Fiorucci, S., Distrutti, E., Bifulco, G., D'Auria, M.V., Zampella, A., Marine sponge steroids as nuclear receptor ligands. Trends Pharmacol Sci 33 (2012), 591–601.
38. [38] Liu, H.M., Kiuchi, F., Tsuda, Y., Isolation and structure elucidation of gymnemic acids, antisweet principles of Gymnema sylvestre. Chem Pharm Bull 40 (1992), 1366–1375.
39. [39] Kazujo, Y., Kayoko, A., Shigenobu, A., Kouji, M., Gymenmic acids V, VI and VII from Gur-ma, the leaves of Gymnema sylvestre R. Br. Chem Pharm Bull 37 (1989), 852–854.
40. [40] Yoshikawa, K., Amimoto, K., Arihara, S., Matsuura, K., Structure studies of new antisweet constituents from Gymnema sylvestre. Tetrahedron Lett 30 (1989), 1103–1106.
41. [41] Yoshikawa, K., Nakagawa, M., Yamamoto, R., Arihara, S., Matsuura, K., Antisweet natural products. V. Structures of gymnemic acids VIII–XII from Gymnema sylvestre R. Br. Chem Pharm Bull 40 (1992), 1779–1782.
42. [42] Schrödinger Release 2013–3: MacroModel, version 10.2, Schrödinger, LLC, New York, NY, 2013.
43. [43] Halgren, T.A., Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 17 (1996), 616–641.
44. [44] Still, W.C., Tempczyk, A., Hawley, R.C., Hendrickson, T., The GB/SA continuum model for solvation. A fast analytical method for the calculation of approximate born radii. J Am Chem Soc 112 (1990), 6127–6129.
45. [45] www.rcsb.org.
46. [46] Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., et al. The protein data bank. Nucleic Acids Res 28 (2000), 235–242.
47. [47] Fradera, X., Vu, D., Nimz, O., Skene, R., Hosfield, D., et al. X-ray structures of the LXRα LBD in its homodimeric form and implications for heterodimer signaling. J Mol Biol 399 (2010), 120–132.
48. [48] Zuercher, W.J., Buckholz, R.G., Campobasso, N., Collins, J.L., Galardi, C.M., et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem 53 (2010), 3412–3416.
49. [49] Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R., Sherman, W., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aid Mol Des 27 (2013), 221–234.
50. [50] Schrödinger Release 2013–3: Schrödinger Suite 2013 Protein Preparation Wizard; Epik version 2.6, Schrödinger, LLC, New York, NY, 2013; Impact version 6.1, Schrödinger, LLC, New York, NY, 2013; Prime version 3.3, Schrödinger, LLC, New York, NY, 2013.
51. [51] Genet, C., Strehle, A., Schmidt, C., Boudjelal, G., Lobstein, A., et al. Structure-Activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 53 (2010), 178–190.
52. [52] Jaye, M.C., Krawiec, J.A., Campobasso, N., Smallwood, A., Qiu, C., et al. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J Med Chem 48 (2005), 5419–5422.
53. [53] Svensson, S., Ostberg, T., Jacobsson, M., Norström, C., Stefansson, K., et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J 22 (2003), 4625–4633.
54. [54] Farnegardh, M., Bonn, T., Sun, S., Ljunggren, J., Ahola, H., et al. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J Biol Chem 278 (2003), 38821–38828.
55. [55] Hoerer, S., Schmid, A., Heckel, A., Budzinski, R.M., Nar, H., Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J Mol Biol 334 (2003), 853–861.
56. [56] Di Micco, S., Renga, B., Carino, A., D'Auria, M.V., Zampella, A., et al. Structural insights into estrogen related receptor-β modulation: 4-methylenesterols from Theonella swinhoei sponge as the first example of marine natural antagonists. Steroids 80 (2014), 51–63.
57. [57] Farid, R., Day, T., Friesner, R.A., Pearlstein, R.A., New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 14 (2006), 3160–3173.
58. [58] Sherman, W., Day, T., Jacobson, M.P., Friesner, R.A., Farid, R., Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49 (2006), 534–553.
59. [59] Sherman, W., Beard, H.S., Farid, R., Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67 (2006), 83–84.
60. [60] Small-Molecule Drug Discovery Suite 2013–3: Schrödinger Suite 2013–3 Induced Fit Docking protocol; Glide version 6.1, Schrödinger, LLC, New York, NY, 2013; Prime version 3.4, Schrödinger, LLC, New York, NY, 2013.
61. [61] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
62. [62] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., et al. Role of AMPactivated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001), 1167–1174.
63. [63] Kalaany, N.Y., Gauthier, K.C., Zavacki, A.M., Mammen, P.P., Kitazume, T., Peterson, J.A., et al. LXRs regulate the balance between fat storage and oxidation. Cell Metab 1 (2005), 231–244.
64. [64] Ducheix, S., Montagner, A., Polizzi, A., Lasserre, F., Marmugi, A., et al. Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J Hepatol 58 (2013), 984–992.
65. [65] Hwahng, S.H., Ki, S.H., Bae, E.J., Kim, H.E., Kim, S.G., Role of adenosine monophosphateactivated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49 (2009), 1913–1925.
66. [66] Laffitte, B.A., Joseph, S.B., Walczak, R., Pei, L., Wilpitz, D.C., et al. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 22 (2001), 7558–7568.
67. [67] Kamble, B., Gupta, A., Patil, D., Khatal, L., Janrao, S., et al. Determination of gymnemagenin in rat plasma using high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral administration of Gymnema sylvestre extract. Biomed Chromatogr 27 (2013), 669–675.